GSK Posts Strong 2025 Results, Raises Dividend and Reaffirms Growth Outlook

GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.

GSK reported a strong 2025, with total sales rising 7% at constant exchange rates to £32.7 billion, driven by a 17% surge in Specialty Medicines, including double-digit growth in respiratory, immunology and inflammation, oncology and HIV, while vaccines and general medicines were broadly stable. Core operating profit grew 11% and core EPS 12%, supported by favourable product mix, SG&A efficiencies, higher royalty income and disciplined but increased R&D investment, while total operating profit and EPS more than doubled largely due to lower legal and credit charges. The company highlighted robust cash generation, sustained shareholder returns through an increased dividend and ongoing £2 billion share buyback, and reaffirmed its 2026 guidance for mid‑single digit sales growth and high‑single digit core profit and EPS growth, alongside a long‑term sales outlook of more than £40 billion by 2031. R&D momentum remained strong with five major FDA approvals in 2025, a bolstered pipeline in respiratory, immunology and oncology through acquisitions and partnerships, and expectations for further acceleration in 2026, including new approvals and pivotal trial readouts, positioning GSK to consolidate its competitive standing in high-value specialty and vaccine markets. An agreement with the US administration to lower prescription drug costs, in exchange for exemption from certain tariffs for three years, is factored into guidance and underscores the company’s efforts to balance US pricing pressure with market access and operational visibility for investors.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on specialty medicines, vaccines and general medicines, with strong positions in respiratory, immunology and inflammation, oncology and HIV, as well as leading vaccines such as Shingrix, meningitis shots and the respiratory syncytial virus (RSV) vaccine Arexvy. The group targets high-growth therapeutic areas while leveraging a broad vaccines and general medicines portfolio and increasingly emphasises R&D-driven innovation to support long‑term sales and earnings expansion.

Average Trading Volume: 8,094,439

Technical Sentiment Signal: Buy

Current Market Cap: £77.67B

For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.